News
TOS-358 demonstrates efficacy in wild-type and mutant PI3Kα cancer models. Nov. 14, 2022. Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent ...
TOS-358 demonstrates efficacy in wild-type and mutant PI3Kα cancer models. Nov. 14, 2022. Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback